Fas expression in lung metastasis from osteosarcoma patients
The authors' animal studies have shown that the metastatic potential of osteosarcoma (OS) cells correlates inversely with Fas expression-that is, Fas-negative cells metastasize but Fas-positive cells do not. One reason for this in the context of OS lung metastases may be that Fas-positive cells...
Gespeichert in:
Veröffentlicht in: | Journal of pediatric hematology/oncology 2005-11, Vol.27 (11), p.611-615 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 615 |
---|---|
container_issue | 11 |
container_start_page | 611 |
container_title | Journal of pediatric hematology/oncology |
container_volume | 27 |
creator | Gordon, Nancy Arndt, Carola A S Hawkins, Douglas S Doherty, Debra K Inwards, Carrie Y Munsell, Mark F Stewart, John Koshkina, Nadezhda V Kleinerman, Eugenie S |
description | The authors' animal studies have shown that the metastatic potential of osteosarcoma (OS) cells correlates inversely with Fas expression-that is, Fas-negative cells metastasize but Fas-positive cells do not. One reason for this in the context of OS lung metastases may be that Fas-positive cells are eliminated by engagement with the Fas ligand (FasL) constitutively expressed on the surface of pneumocytes, whereas Fas-negative tumor cells are not. The purpose of this study was to determine the status of Fas expression in OS lung metastases from patients. Specifically, archived paraffin-embedded specimens of lung metastases from 38 patients with OS were analyzed by immunohistochemistry. Lung nodules from 23 of the 38 patients (60%) were Fas negative, those from 12 patients (32%) were weakly positive, and that from only 1 patient (3%) was strongly positive. Findings in the samples from the remaining two patients (5%) could not be interpreted because of extensive necrosis. Most patients with the weakly positive tumors and the single patient with the strongly positive tumor received chemotherapy prior to lung resection. There was a significant correlation between Fas expression and the administration of preoperative salvage chemotherapy (P = 0.0013). These data indicate that loss of Fas may be one mechanism by which OS cells evade host resistance in the lung. Chemotherapy may induce regression by upregulating Fas. |
doi_str_mv | 10.1097/01.mph.0000188112.42576.df |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68792998</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68792998</sourcerecordid><originalsourceid>FETCH-LOGICAL-c317t-60fd434c5fea4d317f4c1b540ede938642e30079f803934c6c5ce09d376ad543</originalsourceid><addsrcrecordid>eNpFkE1LxDAQhnNQ3HX1L0jx4K01adImES8irgoLXvYesslEK_0y04L-e6O7sMPAwPC8M_AQcs1owaiWt5QV3fhR0FRMKcbKQpSVrAsfTsiSUSlzwZhYkHPEz4RILsozsmB1qUqlxZLcry1m8D1GQGyGPmv6rJ3796yDyWLqBrMQhy4bcIIBbXRDZ7PRTg30E16Q02BbhMvDXJHt-mn7-JJv3p5fHx82ueNMTnlNgxdcuCqAFT6tgnBsVwkKHjRXtSiBUyp1UJTrxNWuckC157K2vhJ8RW72Z8c4fM2Ak-kadNC2todhRlMrqUutVQLv9qCLA2KEYMbYdDb-GEbNny5DmUm6zFGX-ddlfEjhq8OXedeBP0YPrvgvYNFqHg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68792998</pqid></control><display><type>article</type><title>Fas expression in lung metastasis from osteosarcoma patients</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Gordon, Nancy ; Arndt, Carola A S ; Hawkins, Douglas S ; Doherty, Debra K ; Inwards, Carrie Y ; Munsell, Mark F ; Stewart, John ; Koshkina, Nadezhda V ; Kleinerman, Eugenie S</creator><creatorcontrib>Gordon, Nancy ; Arndt, Carola A S ; Hawkins, Douglas S ; Doherty, Debra K ; Inwards, Carrie Y ; Munsell, Mark F ; Stewart, John ; Koshkina, Nadezhda V ; Kleinerman, Eugenie S</creatorcontrib><description>The authors' animal studies have shown that the metastatic potential of osteosarcoma (OS) cells correlates inversely with Fas expression-that is, Fas-negative cells metastasize but Fas-positive cells do not. One reason for this in the context of OS lung metastases may be that Fas-positive cells are eliminated by engagement with the Fas ligand (FasL) constitutively expressed on the surface of pneumocytes, whereas Fas-negative tumor cells are not. The purpose of this study was to determine the status of Fas expression in OS lung metastases from patients. Specifically, archived paraffin-embedded specimens of lung metastases from 38 patients with OS were analyzed by immunohistochemistry. Lung nodules from 23 of the 38 patients (60%) were Fas negative, those from 12 patients (32%) were weakly positive, and that from only 1 patient (3%) was strongly positive. Findings in the samples from the remaining two patients (5%) could not be interpreted because of extensive necrosis. Most patients with the weakly positive tumors and the single patient with the strongly positive tumor received chemotherapy prior to lung resection. There was a significant correlation between Fas expression and the administration of preoperative salvage chemotherapy (P = 0.0013). These data indicate that loss of Fas may be one mechanism by which OS cells evade host resistance in the lung. Chemotherapy may induce regression by upregulating Fas.</description><identifier>ISSN: 1077-4114</identifier><identifier>DOI: 10.1097/01.mph.0000188112.42576.df</identifier><identifier>PMID: 16282894</identifier><language>eng</language><publisher>United States</publisher><subject>Adolescent ; Adult ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Bone Neoplasms - drug therapy ; Bone Neoplasms - metabolism ; Bone Neoplasms - pathology ; Child ; Child, Preschool ; Cisplatin - administration & dosage ; Dendritic Cells - metabolism ; Doxorubicin - administration & dosage ; fas Receptor - metabolism ; Humans ; Ifosfamide - administration & dosage ; Lung Neoplasms - drug therapy ; Lung Neoplasms - metabolism ; Lung Neoplasms - secondary ; Methotrexate - administration & dosage ; Neoplasm Staging ; Osteosarcoma - drug therapy ; Osteosarcoma - metabolism ; Osteosarcoma - secondary ; Paraffin Embedding ; Preoperative Care</subject><ispartof>Journal of pediatric hematology/oncology, 2005-11, Vol.27 (11), p.611-615</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c317t-60fd434c5fea4d317f4c1b540ede938642e30079f803934c6c5ce09d376ad543</citedby><cites>FETCH-LOGICAL-c317t-60fd434c5fea4d317f4c1b540ede938642e30079f803934c6c5ce09d376ad543</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27926,27927</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16282894$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gordon, Nancy</creatorcontrib><creatorcontrib>Arndt, Carola A S</creatorcontrib><creatorcontrib>Hawkins, Douglas S</creatorcontrib><creatorcontrib>Doherty, Debra K</creatorcontrib><creatorcontrib>Inwards, Carrie Y</creatorcontrib><creatorcontrib>Munsell, Mark F</creatorcontrib><creatorcontrib>Stewart, John</creatorcontrib><creatorcontrib>Koshkina, Nadezhda V</creatorcontrib><creatorcontrib>Kleinerman, Eugenie S</creatorcontrib><title>Fas expression in lung metastasis from osteosarcoma patients</title><title>Journal of pediatric hematology/oncology</title><addtitle>J Pediatr Hematol Oncol</addtitle><description>The authors' animal studies have shown that the metastatic potential of osteosarcoma (OS) cells correlates inversely with Fas expression-that is, Fas-negative cells metastasize but Fas-positive cells do not. One reason for this in the context of OS lung metastases may be that Fas-positive cells are eliminated by engagement with the Fas ligand (FasL) constitutively expressed on the surface of pneumocytes, whereas Fas-negative tumor cells are not. The purpose of this study was to determine the status of Fas expression in OS lung metastases from patients. Specifically, archived paraffin-embedded specimens of lung metastases from 38 patients with OS were analyzed by immunohistochemistry. Lung nodules from 23 of the 38 patients (60%) were Fas negative, those from 12 patients (32%) were weakly positive, and that from only 1 patient (3%) was strongly positive. Findings in the samples from the remaining two patients (5%) could not be interpreted because of extensive necrosis. Most patients with the weakly positive tumors and the single patient with the strongly positive tumor received chemotherapy prior to lung resection. There was a significant correlation between Fas expression and the administration of preoperative salvage chemotherapy (P = 0.0013). These data indicate that loss of Fas may be one mechanism by which OS cells evade host resistance in the lung. Chemotherapy may induce regression by upregulating Fas.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Bone Neoplasms - drug therapy</subject><subject>Bone Neoplasms - metabolism</subject><subject>Bone Neoplasms - pathology</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Cisplatin - administration & dosage</subject><subject>Dendritic Cells - metabolism</subject><subject>Doxorubicin - administration & dosage</subject><subject>fas Receptor - metabolism</subject><subject>Humans</subject><subject>Ifosfamide - administration & dosage</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - metabolism</subject><subject>Lung Neoplasms - secondary</subject><subject>Methotrexate - administration & dosage</subject><subject>Neoplasm Staging</subject><subject>Osteosarcoma - drug therapy</subject><subject>Osteosarcoma - metabolism</subject><subject>Osteosarcoma - secondary</subject><subject>Paraffin Embedding</subject><subject>Preoperative Care</subject><issn>1077-4114</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkE1LxDAQhnNQ3HX1L0jx4K01adImES8irgoLXvYesslEK_0y04L-e6O7sMPAwPC8M_AQcs1owaiWt5QV3fhR0FRMKcbKQpSVrAsfTsiSUSlzwZhYkHPEz4RILsozsmB1qUqlxZLcry1m8D1GQGyGPmv6rJ3796yDyWLqBrMQhy4bcIIBbXRDZ7PRTg30E16Q02BbhMvDXJHt-mn7-JJv3p5fHx82ueNMTnlNgxdcuCqAFT6tgnBsVwkKHjRXtSiBUyp1UJTrxNWuckC157K2vhJ8RW72Z8c4fM2Ak-kadNC2todhRlMrqUutVQLv9qCLA2KEYMbYdDb-GEbNny5DmUm6zFGX-ddlfEjhq8OXedeBP0YPrvgvYNFqHg</recordid><startdate>200511</startdate><enddate>200511</enddate><creator>Gordon, Nancy</creator><creator>Arndt, Carola A S</creator><creator>Hawkins, Douglas S</creator><creator>Doherty, Debra K</creator><creator>Inwards, Carrie Y</creator><creator>Munsell, Mark F</creator><creator>Stewart, John</creator><creator>Koshkina, Nadezhda V</creator><creator>Kleinerman, Eugenie S</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200511</creationdate><title>Fas expression in lung metastasis from osteosarcoma patients</title><author>Gordon, Nancy ; Arndt, Carola A S ; Hawkins, Douglas S ; Doherty, Debra K ; Inwards, Carrie Y ; Munsell, Mark F ; Stewart, John ; Koshkina, Nadezhda V ; Kleinerman, Eugenie S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c317t-60fd434c5fea4d317f4c1b540ede938642e30079f803934c6c5ce09d376ad543</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Bone Neoplasms - drug therapy</topic><topic>Bone Neoplasms - metabolism</topic><topic>Bone Neoplasms - pathology</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Cisplatin - administration & dosage</topic><topic>Dendritic Cells - metabolism</topic><topic>Doxorubicin - administration & dosage</topic><topic>fas Receptor - metabolism</topic><topic>Humans</topic><topic>Ifosfamide - administration & dosage</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - metabolism</topic><topic>Lung Neoplasms - secondary</topic><topic>Methotrexate - administration & dosage</topic><topic>Neoplasm Staging</topic><topic>Osteosarcoma - drug therapy</topic><topic>Osteosarcoma - metabolism</topic><topic>Osteosarcoma - secondary</topic><topic>Paraffin Embedding</topic><topic>Preoperative Care</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gordon, Nancy</creatorcontrib><creatorcontrib>Arndt, Carola A S</creatorcontrib><creatorcontrib>Hawkins, Douglas S</creatorcontrib><creatorcontrib>Doherty, Debra K</creatorcontrib><creatorcontrib>Inwards, Carrie Y</creatorcontrib><creatorcontrib>Munsell, Mark F</creatorcontrib><creatorcontrib>Stewart, John</creatorcontrib><creatorcontrib>Koshkina, Nadezhda V</creatorcontrib><creatorcontrib>Kleinerman, Eugenie S</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of pediatric hematology/oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gordon, Nancy</au><au>Arndt, Carola A S</au><au>Hawkins, Douglas S</au><au>Doherty, Debra K</au><au>Inwards, Carrie Y</au><au>Munsell, Mark F</au><au>Stewart, John</au><au>Koshkina, Nadezhda V</au><au>Kleinerman, Eugenie S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Fas expression in lung metastasis from osteosarcoma patients</atitle><jtitle>Journal of pediatric hematology/oncology</jtitle><addtitle>J Pediatr Hematol Oncol</addtitle><date>2005-11</date><risdate>2005</risdate><volume>27</volume><issue>11</issue><spage>611</spage><epage>615</epage><pages>611-615</pages><issn>1077-4114</issn><abstract>The authors' animal studies have shown that the metastatic potential of osteosarcoma (OS) cells correlates inversely with Fas expression-that is, Fas-negative cells metastasize but Fas-positive cells do not. One reason for this in the context of OS lung metastases may be that Fas-positive cells are eliminated by engagement with the Fas ligand (FasL) constitutively expressed on the surface of pneumocytes, whereas Fas-negative tumor cells are not. The purpose of this study was to determine the status of Fas expression in OS lung metastases from patients. Specifically, archived paraffin-embedded specimens of lung metastases from 38 patients with OS were analyzed by immunohistochemistry. Lung nodules from 23 of the 38 patients (60%) were Fas negative, those from 12 patients (32%) were weakly positive, and that from only 1 patient (3%) was strongly positive. Findings in the samples from the remaining two patients (5%) could not be interpreted because of extensive necrosis. Most patients with the weakly positive tumors and the single patient with the strongly positive tumor received chemotherapy prior to lung resection. There was a significant correlation between Fas expression and the administration of preoperative salvage chemotherapy (P = 0.0013). These data indicate that loss of Fas may be one mechanism by which OS cells evade host resistance in the lung. Chemotherapy may induce regression by upregulating Fas.</abstract><cop>United States</cop><pmid>16282894</pmid><doi>10.1097/01.mph.0000188112.42576.df</doi><tpages>5</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1077-4114 |
ispartof | Journal of pediatric hematology/oncology, 2005-11, Vol.27 (11), p.611-615 |
issn | 1077-4114 |
language | eng |
recordid | cdi_proquest_miscellaneous_68792998 |
source | MEDLINE; Journals@Ovid Complete |
subjects | Adolescent Adult Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bone Neoplasms - drug therapy Bone Neoplasms - metabolism Bone Neoplasms - pathology Child Child, Preschool Cisplatin - administration & dosage Dendritic Cells - metabolism Doxorubicin - administration & dosage fas Receptor - metabolism Humans Ifosfamide - administration & dosage Lung Neoplasms - drug therapy Lung Neoplasms - metabolism Lung Neoplasms - secondary Methotrexate - administration & dosage Neoplasm Staging Osteosarcoma - drug therapy Osteosarcoma - metabolism Osteosarcoma - secondary Paraffin Embedding Preoperative Care |
title | Fas expression in lung metastasis from osteosarcoma patients |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-17T17%3A02%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Fas%20expression%20in%20lung%20metastasis%20from%20osteosarcoma%20patients&rft.jtitle=Journal%20of%20pediatric%20hematology/oncology&rft.au=Gordon,%20Nancy&rft.date=2005-11&rft.volume=27&rft.issue=11&rft.spage=611&rft.epage=615&rft.pages=611-615&rft.issn=1077-4114&rft_id=info:doi/10.1097/01.mph.0000188112.42576.df&rft_dat=%3Cproquest_cross%3E68792998%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68792998&rft_id=info:pmid/16282894&rfr_iscdi=true |